Q-VAX Out of Stock until January 2026

CSL Seqirus wishes to advise that Q-VAX® Vaccine will be out of stock and listed as unavailable on the Therapeutic Goods Administration (TGA) Medicines Shortage Database from early November 2026.

Q-VAX® is a biological product made from purified, inactivated C. burnetii bacteria. Due to the complexity of growing the bacteria under controlled conditions, batches can have biological variations that result in their delayed release.

CSL Seqirus are working towards making more stock available as soon as possible and anticipate Q-VAX® Vaccine will be released in late December 2026 and available to customers by early January 2027. Whilst Q-VAX® Vaccine is out of stock, CSL Seqirus will not be accepting or reviewing Q-VAX® supply requests, nor maintaining a wait list. Any requests received during the out-of stock period will not be held. We will communicate with you as soon as stock becomes available.

Although Q-VAX® Skin Test remains available, please do not administer Q-VAX® Skin Test to patients or run Q fever pre-screening clinics, until vaccine supply is reinstated and you have supply of vaccine at your clinic. This is due to the requirement of reading skin tests 7 days after administering the skin test, and then vaccinating eligible individuals post-read.

Download pdf from CSL Sequirus.